RBC Capital Maintains Outperform on Perspective Therapeutics, Lowers Price Target to $27
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza maintains an Outperform rating on Perspective Therapeutics (AMEX:CATX) but lowers the price target from $29 to $27.
August 16, 2024 | 4:06 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital maintains an Outperform rating on Perspective Therapeutics but lowers the price target from $29 to $27.
The Outperform rating suggests continued confidence in the stock's performance, but the lowered price target indicates a slight reduction in expected upside. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100